RxDoctor Payments Data

Maria Ghiuzeli, MD

Hematology & Oncology · Seattle, WANPI 1619186582

Payments from drug & device makers

$87,370in general payments, 2019–2025

Across 16 payments — averaging $5460.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$87K
  • E.r. Squibb & Sons, L.L.C.$19
  • Pfizer$15

What the payments were for

  • Education$34100%

General payments by program year

20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$87,370 in reported general payments places this provider in the 65th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington

Medicare billing

Part B allowed, 2024
$66,441
Medicare patients
130
Services billed
863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydroxyurea32$1,015
Acyclovir31$400
Levofloxacin12$242
Prochlorperazine Maleate14$147
Ondansetron Hcl19$101

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →